

# Community Patient Care and Prescription Orders for End of Life

<b>Objective:</b> to provide prescription orders in advance of a patient being unable to swallow medication; to conserve medication
supply; and to have medications dispensed in a 5-day supply with repeats available. For patients receiving Community Health
Services (home care), in final weeks to days of life with goals consistent with M1 M2.

### **PATIENT INFORMATION**

First Name

Date of Birth (YYYY/MM/DD)

Last Name	

PHN

□ Patient registration on Pharmacare BC Palliative Benefits Confirmed

## **ROUTING INFORMATION**

□ Pharmacv Name & Fax No.

□ Community Health Services (CHS) Fax No.

NOTE: Duplicate Rx for restricted medications must be provided to retail pharmacy

Pharmacy Instruction: \_

### ORDERS

- □ Nurse to insert Foley catheter PRN
- □ Nurse to stop PO meds when unable to swallow and start SUBCUT medication orders as follows:

#### PAIN/ DYSPNEA

- Start with lower dose if frail. Avoid morphine if renal function is very poor (eGFR under 30 mL/min/1.73m<sup>2</sup>)
- For dyspnea: if hypoxic and prognosis is weeks rather than days, consider home oxygen.

#### Option A: Patient is NOT on opioids and currently NOT experiencing pain or dyspnea

- Image: Morphine 2.5 to 5 mg SUBCUT Q1H PRN pain/dyspnea (First line due to HYDROmorphone shortage) Recommended concentration Morphine 10 mg/ml. (Available: 2mg/ml, 10mg/ml, 50mg/ml)
   OR

#### Option B: Patient already receiving or requires regular opioids to treat ongoing pain or dyspnea

- 1. Subcutaneous and/or transdermal opioid orders already in place, no new opioid orders required **OR**

Determine total opioid dose taken in last 24 hours (incl. PRN doses) and convert to subcutaneous route, note oral:SUBCUT is 2:1 ratio. Breakthrough 10% total daily dose.

Drug and Dose:	m	ng SUBCUT	Q4H regular

□ Breakthrough Drug and Dose:\_\_\_\_\_mg SUBCUT Q1H PRN pain/dyspnea

•	If patient continuing fentanyl patch, prov	vide SUBCUT breakthrough order of morphine or HYL	DROmorphone
---	--	---	-------------

# ORDERING PROVIDER

	Name	MSP #	Signature
Date/Time (YYYY/MM/DD):			



# Community Patient Care and Prescription Orders for End of Life

SEVERE PAIN/DYSPNEA (ONLY for patients at risk for rapid escalation of symptoms	5)	
Change frequency of opioid and lorazepam at ordered PRN dose to Q15 min PRN up to 4 doses where symptoms uncontrolled with usual		
breakthrough order (Family to contact Nurse or MD for further instructions)		
Tips when preparing medications for end of life:		
<ul> <li>Do not automatically stop steroids – convert to dexamethasone subcutaneous route if req Dexamethasone: Prednisone using 1:7 scale)</li> </ul>	uired for symptom management. (Note: Convert	
• If patient reliant on anti-seizure medications, consider replacement with regular subcutant	eous benzodiazepine or phenobarbital.	
<ul> <li>To avoid symptoms from discontinuation syndrome, consider changing paroxetine to fluo. due to the longer half-life</li> </ul>	xetine for even just one dose to allow for natural tapering	
Lorazepam may continued to be administered SL by dissolving the tab with a small drop	of water.	
Change REGULAR dosing of current symptom medication from oral to SUBCUT (i.e.		
<ul> <li>□ Haloperidol 0.5 to 1 mg SUBCUT Q4H PRN for nausea (5 mg/mL Dispense 3 mL)</li> <li>□ Haloperidol 0.5 to 1 mg SUBCUT BID Regular (5 mg/mL Dispense 3 mL)</li> <li>ANXIETY</li> <li>□ Lerazonam 0.5 mg 1 mg SL 0.2H DBN for envioty (0.5 mg table Dispense 20 table)</li> </ul>		
□ Lorazepam 0.5 mg – 1 mg SL Q2H PRN for anxiety (0.5 mg tabs Dispense 20 tabs)		
RESTLESSNESS Haloperidol 0.5 – 1 mg SUBCUT Q4H PRN for restlessness ( <i>less sedating</i> ) (5 mg/ml OR	_ Dispense 3 mL)	
□ Methotrimeprazine 6.25 – 12.5 mg SUBCUT Q2H PRN for restlessness (more sedate	ing) (25 mg/mL Dispense 10 mL)	
UPPER AIRWAY SECRETIONS (Select one) □ Glycopyrrolate 0.4 mg SUBCUT Q6H PRN for upper airway secretions (first line) (0.2 OR □ Atropine 1% eye 1-2 drops sublingual Q4H PRN for upper airway secretions (Disper		
LOWER RESPIRATORY TRACT SECRETIONS (pulmonary edema) e.g. congestive hea Furosemide 20 mg SUBCUT Q2H PRN for lower respiratory tract secretions (10mg/m		
REFILLS of non-restricted medications. Number permitted NOTE: Palliative Consultation is available 24/7 for additional support; # available thr	ough hospital switchboards	
ORDERING PROVIDER		
Name MSP #	Signature	
Date(YYYY/MM/DD) Time (HH:MM)		

Approved by Palliative & End of Life Quality & Operations Council May 21 2020